UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma

Rule, S; Cook, G; Russell, NH; Hunter, A; Robinson, S; Morley, N; Sureda, A; ... Peggs, KS; + view all (2019) Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma. British Journal of Haematology , 184 (6) pp. 999-1005. 10.1111/bjh.15723.

[img] Text
Kirkwood Mantle cell Mini Allo final SR for RPS.pdf - ["content_typename_Accepted version" not defined]
Access restricted to UCL open access staff until 18 December 2019.

Download (698kB)

Abstract

Mantle cell lymphoma (MCL) is an aggressive form of non‐Hodgkin lymphoma that remains incurable for the majority of patients. Allogeneic stem cell transplantation (alloSCT) produces long‐term disease‐free remissions for around 30–40% patients, however it is reserved for the treatment of relapsed disease. This study examined the use of front line transplantation for young patients in an attempt to improve outcomes. Twenty‐five patients received an alloSCT using BEAM [BCNU (carmustine), etoposide, cytarabine, melphalan)‐Campath conditioning following permissive induction therapy from both related and unrelated donors. This was a multi‐centre prospective trial. Twenty‐four of 25 patients engrafted with no non‐relapse mortality events by day 100. With a median follow‐up of 60·5 months, there have been six deaths (3 from MCL). The progression‐free survival (PFS) and overall survival were 68% and 80% at 2 years and 56% and 76% at 5 years. PFS was very similar for both sibling and unrelated transplants and there was no difference in PFS between patients with respect to remission status prior to transplantation. Nine (38%) patients experienced acute graft‐versus‐host disease (GVHD) and 14 (58%) experienced chronic GVHD, of which 8 were extensive. Front line alloSCT is feasible but should only be considered for patients at high risk of early progression following conventional therapy.

Type: Article
Title: Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma
Location: England
DOI: 10.1111/bjh.15723
Publisher version: https://doi.org/10.1111/bjh.15723
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: clinical trials, non-Hodgkin lymphoma, stem cell transplantation
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > CRUK Cancer Trials Centre
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology
URI: http://discovery.ucl.ac.uk/id/eprint/10070339
Downloads since deposit
2Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item